India’s largest pharmaceutical company Ranbaxy Laboratories Limited (RLL) has received final approval from the U.S. Food and Drug Administration(FDA) to manufacture and market Cetirizine Hydrochloride Oral Solution (Allergy) and Children’s Cetirizine Hydrochloride Oral Solution (Hives-Relief), 1 mg / mL (OTC) in the US market.

Cetirizine Hydrochloride is indicated for the temporary relief from running nose, sneezing, itching of the nose or throat, and itchy, watery eyes due to hay fever or other upper respiratory allergies. Other indications include relief from itching due to hives (urticaria).

According to data from a leading market research agency, the total market sales for Cetirizine Hydrochloride syrup as a prescription only, are around $157 million annually.

The stock closed today at Rs 479 on BSE, up 1% compared with previous close of Rs 475. It touched an intraday high and low of Rs 483 and Rs 474 respectively.